Wilmington Savings Fund Society FSB bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 45,714 shares of the company's stock, valued at approximately $1,057,000.
Several other institutional investors and hedge funds have also made changes to their positions in KVUE. Riverview Trust Co acquired a new stake in shares of Kenvue in the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue during the 3rd quarter valued at $35,000. Studio Investment Management LLC boosted its holdings in shares of Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock worth $45,000 after purchasing an additional 845 shares during the last quarter. Deseret Mutual Benefit Administrators boosted its holdings in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock worth $45,000 after purchasing an additional 651 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new stake in shares of Kenvue during the third quarter worth $71,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Stock Performance
NYSE KVUE traded down $0.11 during trading hours on Friday, reaching $22.21. 9,184,286 shares of the company were exchanged, compared to its average volume of 17,639,725. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $42.58 billion, a P/E ratio of 40.38, a P/E/G ratio of 2.02 and a beta of 1.36. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business's 50 day simple moving average is $22.95 and its 200-day simple moving average is $21.20.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the firm earned $0.31 EPS. The company's revenue was down .4% compared to the same quarter last year. On average, equities research analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.69%. Kenvue's dividend payout ratio is presently 149.09%.
Wall Street Analyst Weigh In
KVUE has been the topic of several research reports. Barclays raised Kenvue to a "hold" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and lowered their target price for the company from $25.00 to $24.00 in a research note on Thursday. Bank of America raised their target price on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Royal Bank of Canada upgraded Kenvue from a "hold" rating to a "moderate buy" rating in a research note on Monday, December 9th. Finally, Piper Sandler lifted their price target on Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Kenvue presently has an average rating of "Hold" and an average price target of $22.64.
Read Our Latest Analysis on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
